DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over the ...

DexCom may be a major player in the market for continuous glucose monitors, but that doesn’t means it’s shielded from concerns over slower-than-expected growth. Interim CEO Jake Leach indicated on ...

As reimbursement broadens globally, DexCom is well positioned to drive sustained user growth and strengthen its leadership in ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust first-quarter 2024 performance, along with a series of favorable coverage decisions ...

Feb 13 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with ...

DexCom (NASDAQ:DXCM) stock experienced a significant 16% surge on Friday following its Q1 earnings release and a share buyback announcement. The company’s first-quarter sales reached $1.04 billion, ...

Feb 12 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat Wall Street estimates for fourth-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring ...

A trio of stocks made an impressive leap in their Benzinga Edge value scores this week, with one standout making a 138% jump. The three companies that have caught the eye of value investors are TAL ...